Here’s a bold statement: the future of rheumatology treatment might just lie in weight-loss drugs. But here’s where it gets controversial—could these medications, traditionally used for metabolic health, revolutionize how we manage conditions like gout and rheumatoid arthritis? Let’s dive in.
Exciting findings from ACR Convergence 2025 reveal that weight-loss drugs, specifically novel anti-obesity medications (AOMs), are showing remarkable potential in rheumatology. And this is the part most people miss—these drugs don’t just help shed pounds; they could significantly reduce serum urate levels in patients with gout and baseline hyperuricemia. This dual benefit is a game-changer for those struggling with both obesity and rheumatic conditions.
Researchers analyzed data from the Mass General Brigham (MGB) electronic health record (EHR) database, a not-for-profit integrated health system in Greater Boston. MGB operates two prestigious academic medical centers—Massachusetts General Hospital and Brigham and Women’s Hospital—along with specialty and community hospitals, home care services, urgent care, and a licensed health plan serving Massachusetts and southern New Hampshire. Their study focused on patients with gout and baseline hyperuricemia who started treatment with novel AOMs like semaglutide or tirzepatide.
Out of 22 patients identified, the average age was 54.6 years, with 77.3% being male and a mean baseline BMI of 39.3 kg/m². Half were treated for obesity, while the other half received the medication for type 2 diabetes, though most had comorbid obesity. Over an average treatment period of 258 days, the results were striking: 31.8% lost 5–10% of their body weight, 22.7% lost more than 10%, and 45.5% lost 5% or less.
Here’s the kicker—each kilogram of weight loss was linked to a 0.13 mg/dL drop in serum urate, and every one-unit decrease in BMI was associated with a 0.41 mg/dL decline. Patients who lost more than 10% of their body weight saw a mean 2.36 mg/dL greater reduction in serum urate compared to those who lost less than 5%. This suggests that novel AOMs could be a powerful multi-purpose tool for patients with gout and obesity, though larger-scale studies are needed to confirm these findings.
But wait, there’s more. GLP-1 receptor agonists and SGLT2 inhibitors were hot topics at ACR this year, with presentations exploring their role in managing rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis, and osteoarthritis. Dr. Shreya Sakthivel’s retrospective study, for instance, examined how SGLT2 inhibitors and GLP-1 agonists impact RA flares in patients on DMARD therapy.
Using real-world data from the TriNetX research network (2019–2024), the study analyzed adults with RA who had more than 12 months of follow-up after starting DMARD therapy. Participants were divided into three groups: DMARDs alone, DMARDs plus an SGLT2 inhibitor, and DMARDs plus a GLP-1 receptor agonist. RA flares were assessed using a composite index that included factors like oral prednisone use, elevated C-reactive protein, and DMARD escalation.
The results? SGLT2 inhibitors were associated with a significant reduction in RA flares, while GLP-1 agonists showed a non-significant trend toward flare reduction. Here’s the controversial part—could GLP-1 therapies, already known for improving cardiometabolic health, also play a role in managing autoimmune and inflammatory conditions? Dr. Sakthivel believes so, highlighting their potential as dual-action agents.
Now, here’s a thought-provoking question for you—as metabolic health and rheumatic diseases increasingly intersect, should we rethink how we approach treatment for patients with both conditions? Share your thoughts in the comments below. The conversation is just getting started.
